Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June 29

POSTE E SIk 2

12348 Is saquinavira weak protease inhibitor?
Oscar GarciaMesina*; D. Pugliese; G. Ortega; R. Carlevaro; M. Oliva;
J. Benetucci, Argentina
12349 Tolerability of combination therapy with protease inhibitors
in HIV(+) patients
Jozep Higersberger*; A. Ignatowska; T. Rzeszkowicz-Wasilewska;
I. Weber-Kaniuk; A. Bednarska; E. Bakowska; A. Horban, Poland
12350 indinavir (Crixivan ) in combination with two nucleoside reverse
transcriptase inhibitors (NRTIs) in HIV-infected patients
Andrzej Horban*; A. Ignatowska; D. Latarska; J. Higersberger;
E. Burkacka; A. Zg6dka; A. Lipniaki, Poland
12351 STADI:Sustained efficacy of once daily administration of didanosine
in combination with stavudine
Jacques Reynes*; R. Denisi; A. Bicart-see; J. Izopet; I. Pellegrin;
M. Segondy; J.R. Stadi-Group, France
12352 DDI once daily vs twice daily alone and also with hydroxyurea once daily
Janice Rusnak*; A. Berry; B. Stinnette; K. Sharkey; S. Zhov; K. Dyall;
M. Vahey, USA
12353 Safety and tolerance ofabacavir (1592, ABC) alone and in combination
therapy of HIV-infection
Seth Hetherington*; H.M. Steel; S. Lafon; W. Spreen; G. Pearce, USA
12354 Stavudine penetrates the blood-brain barrier
Elmar Straube; B.K. Kuhlmann; M. W. Weimann; R.H. Hoetelman;
P Von Wussow, Germany
12355 Stavudine entry into cerebrospinal fluid of HIV-infected subjects after
single and multiple doses
Kathleen Brady*;J. Aldrich; R. Broston; R.R. MacGregor, USA
12356 Inhibition of lymphoma using ribonucleotide reductase inhibitors (RRIs)
in the murine model of immunodeficiency disease - MAIDS
Vincent Gallicchio*; C. Mayhew; H.L. Elford, USA
12357 An Open-label randomized study of Rescriptor (DLV,delavirdine
mesylate) in triple and quadruple combinations with zidovudine (ZDV),
indinavir (IDV) and lamivudine (3TC) in HIV-1 infected individuals
Patrick Daly; S.L. Green; W.W. Freimuth; M.A. Conklin; D.C. Huang;
L.K. Wathen, USA
12358 (-)-Beta-D-2,6-diaminopurine dioxolane is a prodrug ofdioxolane
guanosine a novel inhibitor of HIV-1 replication
Laura Lynn Kiefer*; Phillip A. Furman; G.R. Painter; I. Liberman;
E.L. Hill; K.B.E. Borroto; C.K. Chu; R.F. Schinazi, USA
12359 Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for
efavirenz (DMP 266) in combination with indinavir (IDV) DMP 266-003,
Cohort IV]
Sharon Riddler*; J. Kahn; C. Hicks; D. Havlir; D. Stein;J. Horton;
N. Ruiz, USA
12360 Once-daily dosing of nevirapine: A retrospective, cross-study analysis
Alex Dusek*; D. Hall; M. Lamson; M. Myers, USA
12361 Patients with higher baseline pVL are less likely to have a virologic
response in a Meta-Analysis of two trials ofZDV/ddl vs ZDV/ddl/NVP
Janet Raboud; J.S.G. Montaner; S. Rae; R. Bucciardini; M. Floridio;
D. Ricciardulli;S. Vella, Canada

12362 Drug combination studies on MKC-442 with RT inhibitors in long-term
culture of HIV-1-infected cells
Satoshi Yuasa*; K. Nakade;J. Piras; M. Baba, Japan

12363 Correlations between CD4 and RNA response in antiretroviral-naive
patients with very advanced disease (trial ISS 047)
Vincenzo Fragola*; Marco Floridia; R. Bucciardini; D. Ricciardulli;
L.E. Weimer; C.M. Galluzzo; M.F. Pirillo; M. Andreotti, Italy
12364 How low is low enough? Suppression of plasma viral load below 20
copies/mL is necessary for long term virologic response
Julio S.G. Montaner*; V. Montessori; J.M. Raboud; B. Conway;
P Robinson; M. Myers; D. Hall, Canada
12365 Predictors of duration ofvirologic suppression in a Meta-Analysis
of two trials of ZDV/ddl vs ZDV/ddl/NVP
Janet Raboud; J.S.G. Montaner; S. Rae; R. Bucciardini; M. Floridio;
S. Vella, Canada
12366 Combination anti-HIV interactions and resistance profile of
the nonnucleoside RT inhibitor (+)-calanolide A
Robert Buckheit*; J. Russell; V.F. Boltz; L.A. Pallansch; Z.Q. Xu;
M. Flavin, USA
12367 Meta-analysis of two trials of ZDV/ddl vs ZDV/ddl/NVP
Sandra Rae*; S. Vella; M. Floridia; R. Bucciardini; J.M. Raboud;
J.S.G. Montaner, Canada
12368 Long-term follow-up of patients treated with nevirapine (NVP) based
combination therapy within the INCAS trial
Patrick Robinson*; Julio S.G. Montaner, Canada
12369 Efficacy of nevirapine (NVP)+3TC+ZDV in nucleoside-experienced
patients: An open label study
Jose Estrada* M. Pacheco; C. Lavalle, Mexico
12370 Novel antiretroviral compounds that inhibit nuclear localization
of HIV-1 genome
Omar Haffar*; M.D. Smithgall; L. Dubrovsky; M. Burkinsky, USA
12371 Suppression of HIV replication and cell proliferation leads to minimal
levels of proviral DNA and to immune recovery
Franco Lori*; H. Jessen; M. Clerici; J. Lieberman; B. Walker; R.F. Siliciano;
J. Lisziewicz, Italy
12372 Urologic complaints in relation to indinavir plasma levels
in HIV-infected patients
Jeanne Dieleman*; I.C. Gyssens; M.E.M. van der Ende; S. de Marie;
D.M. Burger, The Netherlands
12373 Changes in body habitus in HIV(+) women after initiation of protease
inhibitor therapy
Krista Dong*; M.M. Flynn; B.P. Dickinson; J.D. Rich; K. Tashima;
T.P. Flanigan; C.C.J. Carpenter, USA
12374 Evaluation of potential interactions between MKC-442 and zidovudine
(ZDV)-lamivudine (3TC),and stavudine (d4T)-didanosine (ddl) in healthy
volunteers
Cary Moxham*; M.R. Blum; DJ. Kargl; J.B. Quinn; F.S. Rousseau;
D.W. Barry, USA
12375 Metabolic changes in HIV-infected patients treated with protease
inhibitors
Enos Bernasconi*; Antonio Carota; L. Magenta; M. Pons; M. Russotti;
T. Moccetti; E. Bernasconi, Switzerland
12376 Birth defects and zidovudine use in HIV+ women in New York state
medicaid

CraigJ. Newschaffer*;J. Cocroft; W. W. Hauck; C.E. Anderson;
T.R. Fanning; B.J. Turner, USA

36

12th World AIDS Conference Geneva